Jim Tullis | Founder
Jim founded Tullis Health Investors in 1986. Since then he has led six separate health care focused private equity funds and has invested successfully across the health care sector. Before establishing Tullis Health Investors, Jim worked on Wall Street where he managed health care investment research at Morgan Stanley and later at E.F. Hutton & Co.
John Tullis | President
John is President of Tullis Health Investors. In addition to his general management responsibilities, he leads the investment team. John is particularly focused on investments in medical devices and healthcare specific service platforms, where he works with and engages companies, offering guidance and global perspective. John is currently on the boards of CareSync, Inc and SureFire Medical, Inc.
Neil Ryan | Venture Partner
Neil joined Tullis in 2001. He has experience investing successfully across the health care industry for more than 30 years, having earlier co-founded two well known venture capital funds: Oxford Partners, and its successor, Oxford Bioscience Partners. He was previously president of GTE New Ventures Corporation and a senior vice president of GTE Corporation.
David Leffell | Venture Partner
Dr. Leffell is the David Paige Smith Professor Dermatology and Surgery at the Yale School of Medicine. He is Chief of the Section of Dermatologic Surgery and Cutaneous Oncology in the School of Medicine and attending physician at Yale New Haven Hospital. For 15 years he was CEO of the Yale Medical Group and is widely credited with transforming the faculty practice into a competitive nationally recognized physician practice group.
Barbara Bierer | Venture Partner
Dr. Bierer is Professor of Medicine at Harvard Medical School and Brigham and Women’s Hospital in Boston, Massachusetts, and a hematologist/oncologist. She is the faculty co-chair of the Multi-Regional Clinical Trials Center at Harvard University (Harvard MRCT) and The Director of the Regulatory Foundations, Ethics and Law Program of The Harvard Clinical and Translational Sciences Center. She founded the BWH Innovation Hub (iHub).
Tina Nova | Venture Partner
Tina Nova, PhD, currently serves as President & CEO of Molecular Stehoscope. She was previously Senior Vice President & General Manager of the Oncology Business Unit of Illumina, Inc. and before that she was President & CEO of Genoptix, Inc., a Novartis Company, which she co-founded in 2000. Genoptix was a portfolio company in the Tullis Dickerson II Fund. Dr. Nova was also a co-founder of Nanogen, Inc.